Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
WALTHAM, Mass., April 26, 2018 -- Histogenics Corporation (Nasdaq:HSGX), a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function, announced it will report its first quarter 2018 financial results on May 10, 2018, before the U.S. financial markets open.
The Company will host a conference call on Thursday, May 10, 2018 at 8:30 a.m. EDT. To access the live call, please dial (877) 930-8064 (domestic) or (253) 336-8040 (international) and provide the conference ID “8376199” five to ten minutes before the start of the call.
A live audio webcast of the presentation will be available via the “Investor Relations” page of the Histogenics website, www.histogenics.com, or by clicking here. A replay of the webcast will be archived on Histogenics’ website for approximately 45 days following the call.
About Histogenics Corporation
Histogenics (Nasdaq:HSGX) is a leader in the development of restorative cell therapies that may offer rapid-onset pain relief and restored function. Histogenics’ lead investigational product, NeoCart®, is designed to rebuild a patient’s own knee cartilage to treat pain at the source and may prevent a patient’s progression to osteoarthritis. NeoCart is one of the most rigorously studied restorative cell therapies for orthopedic use. Histogenics recently completed enrollment of its NeoCart Phase 3 clinical trial and expects to report top-line, one-year superiority data in the third quarter of 2018. NeoCart is designed to perform like articular hyaline cartilage at the time of treatment, and as a result, may provide patients with more rapid pain relief and accelerated recovery as compared to the current standard of care. Histogenics’ technology platform has the potential to be used for a broad range of additional restorative cell therapy indications. For more information on Histogenics and NeoCart, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
